Yang Ronglu, Liu Wu, Zhou Yi, Cheng Bin, Liu Shiyi, Wu Ruiying, Liu Yongjun, Li Jinhu
Department of Traditional Chinese Medicine, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, 230001, China.
Beijing Hospital of Traditional Chinese Medicine, Capital Medical University, Beijing, 100010, China.
J Ethnopharmacol. 2025 Mar 13;343:119478. doi: 10.1016/j.jep.2025.119478. Epub 2025 Feb 11.
Diabetic kidney disease (DKD) is one of the main types of chronic kidney disease, which seriously affects the quality of life of patients. Shen-Qi-Huo-Xue formula (SQHXF), based on the Shen-Qi-Di-Huang decoction, is a traditional Chinese medicine formula for DKD. This study explored the mechanism of action of SQHXF on DKD through analysis of drug components, in vivo and in vitro experiments.
To elucidate the regulatory mechanisms of HIF-1α/HIF-2α homeostasis on ferroptosis and epithelial-mesenchymal transition (EMT) in renal tubular epithelial cells and the mechanism of action of SQHXF against DKD.
The components of SQHXF were analyzed using UPLC-Q Exactive HF/MS. The effects of SQHXF on renal function, urinary proteins, glucose-lipid metabolism, hepatic function, renal tissue hypoxia, ferroptosis and EMT were analyzed following gavage of DKD model mice with different SQHXF doses. The effects of changes in HIF-1α and HIF-2α expression on ferroptosis and EMT, as well as the modulatory effects of SQHXF-containing serum, were assessed in vitro. The potential feedback mechanism of HIFs/ferroptosis/EMT was elucidated using HIF-1α knockdown and a ferroptosis inhibitor.
One-hundred and fifty compounds in SQHXF were tested for bloodstream entry. In vivo study showed that SQHXF was able to reduce creatinine, uric acid, fasting plasma glucose, 24-h urinary protein, low-density lipoprotein cholesterol, and aspartate aminotransferase levels, up-regulate HIF-1α, down-regulate HIF-2α, reduce ferroptosis, and alleviate renal fibrosis and EMT in tubular epithelial cells. HIF-1α/HIF-2α imbalance promoted ferroptosis and EMT in HK-2 cells, which was attenuated by SQHXF-containing serum. HIF-1α knockdown decreased HIF-2α expression and reduced ferroptosis and EMT. Inhibition of ferroptosis reduced EMT but failed to regulate HIF-1α and HIF-2α.
SQHXF alleviated ferroptosis and EMT, improved liver and kidney function, reduced proteinuria, and alleviated renal lesions by maintaining equilibrium between HIF-1α and HIF-2α.
糖尿病肾病(DKD)是慢性肾病的主要类型之一,严重影响患者的生活质量。基于肾气地黄汤的参芪活血方(SQHXF)是一种用于治疗DKD的中药方剂。本研究通过药物成分分析、体内和体外实验探索了SQHXF对DKD的作用机制。
阐明缺氧诱导因子-1α(HIF-1α)/缺氧诱导因子-2α(HIF-2α)稳态对肾小管上皮细胞铁死亡和上皮-间质转化(EMT)的调控机制以及SQHXF抗DKD的作用机制。
采用超高效液相色谱-四级杆飞行时间质谱联用仪(UPLC-Q Exactive HF/MS)分析SQHXF的成分。用不同剂量的SQHXF灌胃DKD模型小鼠后,分析其对肾功能、尿蛋白、糖脂代谢、肝功能、肾组织缺氧、铁死亡和EMT的影响。在体外评估HIF-1α和HIF-2α表达变化对铁死亡和EMT的影响以及含SQHXF血清的调节作用。使用HIF-1α基因敲低和铁死亡抑制剂阐明HIFs/铁死亡/EMT的潜在反馈机制。
检测了SQHXF中150种化合物的入血情况。体内研究表明,SQHXF能够降低肌酐、尿酸、空腹血糖、24小时尿蛋白、低密度脂蛋白胆固醇和天冬氨酸转氨酶水平,上调HIF-1α,下调HIF-2α,减少铁死亡,并减轻肾小管上皮细胞的肾纤维化和EMT。HIF-1α/HIF-2α失衡促进了人肾小管上皮细胞系(HK-2)细胞的铁死亡和EMT,含SQHXF血清可使其减轻。敲低HIF-1α可降低HIF-2α表达,并减少铁死亡和EMT。抑制铁死亡可减少EMT,但未能调节HIF-1α和HIF-2α。
SQHXF通过维持HIF-1α和HIF-2α之间的平衡,减轻铁死亡和EMT,改善肝肾功能,减少蛋白尿,并减轻肾脏病变。